Skip to main content

Advertisement

Table 6 Studies of carboplatin in CCRT for locally advanced cervical cancer

From: Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand

Studies N Stage Treatment results Late Toxicities
Cetina et al. [11] 85 (high risk of poor renal dysfunction) IB2 4.7 % OS 81 % -
IIA 8.2 %
IIB 41.1 %
IIIA 4.7 %
IIIB 38.8 %
IVA 2.5 %
Cetina et al. [12] 59 (elderly patients) IB2 8.4 % 30-months OS 63 % -
IIA 13.5 %
IIB 52.5 %
IIIA 3.3 %
IIIB 18.6 %
Katanyoo et al. [13] 148 IIB 50.7 % 2-years PFS 75.1 % Grade 3–4 GI 10.1 %
IIIB 48.0 % 5-years PFS 63 % Grade 3–4 GU 0.7 %
IVA 1.3 % 2-years OS 81.9 %
5-years OS 63.5 %
Sangkittipaiboon et al. [14] 105 IIB 83 5-years DFS 52.38 % Grade 3–4 GI 3.2 %
III, 19 5-years OS 56.19 % Grade 3–4 GU 0 %
IVA 3
Our study 76 IIB 56.6 % 3-years DFS 78.9 % Grade 3–4 GI 6.5 %
IIIA 2.6 % 3-years OS 89.5 % Grade 3–4 GU 6.5 %
IIIB 40.8 %
  1. Note: PFS progression-free survival, DFS Disease-free survival, OS overall survival, GI gastrointestinal, GU genitourinary